NanoString Technologies Prices Initial Public Offering

NanoString Technologies Prices Initial Public Offering

SEATTLE--(BUSINESS WIRE)--June 25, 2013-- NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its initial public offering of 5.4 million shares of common stock at a price to the public of $10.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 810,000 shares to cover over-allotments, if any.

The bookrunning managers of the offering are J.P. Morgan and Morgan Stanley, and the co-managers are Leerink Swann and Robert W. Baird & Co. Incorporated. NanoString Technologies common stock will trade on The NASDAQ Global Market under the symbol "NSTG."

The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, telephone: 1-866-718-1649, or email: [email protected]

A registration statement relating to this offering of common stock has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

CONTACT: For NanoString Technologies Lynn Pieper of Westwicke Partners, 415-202-5678

[email protected]

SOURCE: NanoString Technologies, Inc.

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.